{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:03:37Z","timestamp":1779685417433,"version":"3.53.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive Impairment (CI) is an increasingly serious public health problem in an aging society. Its rising incidence rate is closely linked to functional decline and increased mortality risk. Because of its insidious onset and irreversible progression, early identification is particularly crucial. Neuroinflammation and vascular injury play important roles in the occurrence and development of CI. Galectin-3 (Gal-3), as a biomarker involved in the inflammatory response and vascular lesion process, may have potential value in the early prediction and risk assessment of CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Seven databases were systematically retrieved from their establishment until March 8, 2026. Two independent researchers conducted literature screening, data extraction, and quality evaluation using the Newcastle-Ottawa Scale. The combined effect size was calculated using the weighted mean difference (WMD) or standardized mean difference (SMD), with a 95% confidence intervals (CIs). Heterogeneity was evaluated using the chi-square (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      ) test (Cochran\u2019s Q) and the inconsistencies index test (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      ), and publication bias was assessed using funnel plots and Egger\u2019s regression tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This systematic review included nine studies comprising 877 patients with cognitive impairment (CI) and 715 healthy controls. The meta-analysis demonstrated that peripheral Gal-3 levels were significantly higher in the CI group compared with controls (WMD: 0.85; 95%CI: 0.42\u20131.28;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001), despite substantial heterogeneity across studies (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f98%). Subgroup analyses further revealed that Gal-3 levels were significantly elevated in CI with vascular risk factors (WMD: 1.76; 95%CI: 0.10\u20133.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.04), whereas no statistically significant difference was observed in CI without vascular risk factors (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.06). Regarding specific disease types, Gal-3 levels were significantly higher in patients with mild cognitive impairment (MCI) (WMD: 0.72; 95%CI: 0.04\u20131.40;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.04), but not in those with Alzheimer\u2019s disease (AD) (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.11).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated Gal-3 levels are significantly associated with cognitive impairment and may serve as a convenient and effective biomarker for its early detection, particularly in CI with vascular risk factors and MCI. However, the evidence remains insufficient for AD, warranting further large-scale studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261293666<\/jats:ext-link>\n                      , identifier CRD420261293666.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1851363","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:36:14Z","timestamp":1779683774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of Galectin-3 in cognitive impairment: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying-ying","family":"Yang","sequence":"first","affiliation":[{"name":"School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xue","family":"Zeng","sequence":"additional","affiliation":[{"name":"School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Affiliated Sichuan Provincial Rehabilitation Hospital of Chengdu University of TCM","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia-lian","family":"Huang","sequence":"additional","affiliation":[{"name":"Affiliated Sichuan Provincial Rehabilitation Hospital of Chengdu University of TCM","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-xi","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-le","family":"Mao","sequence":"additional","affiliation":[{"name":"Affiliated Sichuan Provincial Rehabilitation Hospital of Chengdu University of TCM","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-qiu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-li","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3892\/br.2020.1315","article-title":"Total flavonoids of Selaginella pulvinata alleviates cognitive impairment in mice","volume":"13","author":"Zhang","year":"2020","journal-title":"Biomed Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.vhri.2025.101130","article-title":"Evaluating the cost-effectiveness of pharmacological therapy in Alzheimer disease in Brazil","volume":"49","author":"Price","year":"2025","journal-title":"Value Health Reg Issues"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0324130","DOI":"10.1371\/journal.pone.0324130","article-title":"Cognitive impairment influencing factors in the middle-aged and elderly population in China: evidence from a National Longitudinal Cohort Study","volume":"20","author":"Zu","year":"2025","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2014beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jocn.2019.08.032","article-title":"A preliminary data: evaluation of serum galectin-3 levels in patients with idiopathic Parkinson's disease","volume":"70","author":"Yazar","year":"2019","journal-title":"J Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/biom10030389","article-title":"Galectin-3 as a next-generation biomarker for detecting early stage of various diseases","volume":"10","author":"Hara","year":"2020","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/ijmm.2017.3311","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int J Mol Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.celrep.2015.02.012","article-title":"Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation","volume":"10","author":"Burguillos","year":"2015","journal-title":"Cell Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/0028-3886.177600","article-title":"Galectin-3, an important yet unexplored molecule in drug resistant epilepsy","volume":"64","author":"Tripathi","year":"2016","journal-title":"Neurol India"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2022.09.018","article-title":"Involvement of Galectin-3 in neurocognitive impairment in obstructive sleep apnea via regulating inflammation and oxidative stress through NLRP3","volume":"101","author":"Zong","year":"2023","journal-title":"Sleep Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/01.hjh.0000570572.44178.0a","article-title":"Biomarkers of ventricular-arterial fibrosis were inverse correlated with cognitive function independently of arterial stiffness","volume":"37","author":"Cheng","year":"2019","journal-title":"J Hypertens"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fnins.2018.00430","article-title":"Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders","volume":"12","author":"Ashraf","year":"2018","journal-title":"Front Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/alz.13536","article-title":"Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity","volume":"20","author":"Borrego-\u00c9cija","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e70765","DOI":"10.1002\/cns.70765","article-title":"Peripheral signatures of multidimensional pathology in symptomatic and asymptomatic Creutzfeldt\u2013Jakob disease","volume":"32","author":"Chen","year":"2026","journal-title":"CNS Neurosci Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jdi.13256","article-title":"Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level","volume":"11","author":"Ma","year":"2020","journal-title":"J Diabetes Investig"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1038\/s41467-019-11441-0","article-title":"Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease","volume":"10","author":"Siew","year":"2019","journal-title":"Nat Commun"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5827812","DOI":"10.1155\/2021\/5827812","article-title":"Serum galectin-3 as a potential predictive biomarker is associated with poststroke cognitive impairment","volume":"2021","author":"Wang","year":"2021","journal-title":"Oxidative Med Cell Longev"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/1533317513495107","article-title":"Elevated galectin-3 levels in the serum of patients with Alzheimer's disease","volume":"30","author":"Wang","year":"2015","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s13760-020-01477-1","article-title":"Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report","volume":"121","author":"Yazar","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40618-024-02506-z","article-title":"Development and validation of Galectin-3 and CVAI-based model for predicting cognitive impairment in type 2 diabetes","volume":"48","author":"Zhou","year":"2025","journal-title":"J Endocrinol Investig"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/s1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2019.03.012","article-title":"Toll-like receptors in the pathogenesis of neuroinflammation","volume":"332","author":"Kumar","year":"2019","journal-title":"J Neuroimmunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3233\/jad-160912","article-title":"Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative diseases","volume":"55","author":"Nilson","year":"2017","journal-title":"J Alzheimer's Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2016.04.200","article-title":"Energy metabolism and inflammation in brain aging and Alzheimer's disease","volume":"100","author":"Yin","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/s41467-021-23111-1","article-title":"Transcriptional signature in microglia associated with a\u03b2 plaque phagocytosis","volume":"12","author":"Grubman","year":"2021","journal-title":"Nat Commun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1074\/jbc.M110.135244","article-title":"Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity","volume":"286","author":"Maezawa","year":"2011","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbi.2016.11.005","article-title":"Genetic deletion of galectin-3 enhances neuroinflammation, affects microglial activation and contributes to sub-chronic injury in experimental neonatal focal stroke","volume":"60","author":"Chip","year":"2017","journal-title":"Brain Behav Immun"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1007\/s12035-019-1527-0","article-title":"Delayed Galectin-3-mediated reprogramming of microglia after stroke is protective","volume":"56","author":"Rahimian","year":"2019","journal-title":"Mol Neurobiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.brainres.2011.01.049","article-title":"Galectin-3 expression in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia, and its inhibition by hypothermia","volume":"1382","author":"Satoh","year":"2011","journal-title":"Brain Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/glycob\/cwu111","article-title":"Galectin-3: an emerging all-out player in metabolic disorders and their complications","volume":"25","author":"Pugliese","year":"2015","journal-title":"Glycobiology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1523\/jneurosci.1498-12.2012","article-title":"Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury","volume":"32","author":"Lalancette-H\u00e9bert","year":"2012","journal-title":"J Neurosci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1517\/13543776.2014.947961","article-title":"Galectin-3 inhibitors: a patent review (2008-present)","volume":"24","author":"Blanchard","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1046\/j.1523-1755.2000.07706.x","article-title":"Role of galectin-3 as a receptor for advanced glycosylation end products","volume":"77","author":"Pricci","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"41689","DOI":"10.1038\/srep41689","article-title":"Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration","volume":"7","author":"Yip","year":"2017","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol Rev"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.drudis.2017.11.004","article-title":"Galectin-3: mediator of microglia responses in injured brain","volume":"23","author":"Rahimian","year":"2018","journal-title":"Drug Discov Today"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","article-title":"Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction","volume":"25","author":"Nation","year":"2019","journal-title":"Nat Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1002\/jcp.27910","article-title":"Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrin \u03b21-RhoA-JNK signaling activation","volume":"234","author":"Chen","year":"2019","journal-title":"J Cell Physiol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/atvbaha.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2012.12.008","article-title":"Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling","volume":"1496","author":"Wesley","year":"2013","journal-title":"Brain Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/glia.23782","article-title":"Dystrophic microglia in late-onset Alzheimer's disease","volume":"68","author":"Streit","year":"2020","journal-title":"Glia"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww349","article-title":"An early and late peak in microglial activation in Alzheimer's disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1851363\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:36:16Z","timestamp":1779683776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1851363\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":52,"alternative-id":["10.3389\/fneur.2026.1851363"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1851363","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1851363"}}